#Cannabis Stock News: Jenex (TSXV: $JEN.H) to
Test TherOZap(TM) Working Prototype and Topical Cannabidiol Oil Against the
Zika and West Nile Viruses
Toronto, Ontario - April 18, 2017 (Newsfile Corp.)
(Investorideas.com Newswire) NOT FOR DISSEMINATION OR DISTRIBUTION IN THE
UNITED STATES- The Jenex Corporation (TSXV: JEN.H) ("Jenex" or the
"Company"), a progressive medical device technology company, would
like to report the testing of a topical cannabidiol ("CBD") oil from
hemp with Jenex's platform technology, including Jenex's TherOZap™ device. The
topical cannabidiol oil will be included in the lab tests, to be conducted
through University Health Network and coordinated through Techna Institute at
UHN located in Toronto, Ontario, to determine the effectiveness at inactivating
both the Zika and West Nile viruses as previously announced on April 7th, 2017.
There is a growing body of clinical research demonstrating CBD's
potential therapeutic uses against viruses. The clinical research is revealing
and is demonstrating that CBD can have positive health effects as CBD increases
nitric oxide levels in the human body which may prove to be an effective
treatment to combat viral infections such as the Zika and West Nile viruses.
There are high levels of CBD in hemp but almost no tetrahydrocannabinol (THC),
the psychoactive component that is prevalent in cannabis.
Jenex will work with partners in the medical marijuana industry
to license a topical CBD oil or working through formulators Jenex will create
its own topical CBD oil to be used with the TherOZap™ device. Several natural
health products in topical formulations with unique delivery systems could be
developed.
Rob Fia, CEO commented:
"We are excited to test our platform technology, including
our TherOZap™ device, with a topical cannabidiol oil. Our platform technology
combined with a unique CBD topical delivery system may prove beneficial in
potentially combating the increasingly troublesome Zika virus problem now
affecting many parts of the world."
RISKS AND UNCERTAINTIES INHERENT TO THE MEDICAL MARIJUANA
BUSINESS
The Company plans to continue its principal business of
developing its consumer product platform technology. The Company's pursuit of
the use of hemp oil with CBD is supplementary to the consumer product platform
technology business it is currently engaged in. The board of directors have
approved the Company's testing of hemp oil with CBD and to the Company's
knowledge, this is the only approval required for the Company's pursuit of opportunities
to test hemp oil with CBD with its platform technology. There are risks and
uncertainties inherent to the medical marijuana businesses and it should be
noted that the Company does not intend to acquire a medical marijuana license.
Jenex received a Class II medical device status from the FDA for
its platform technology that is indicated for the relief of the pain, itch, and
inflammation from over 20,000 different insect stings and bites, (including
bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received
approval for the above claims from FDA (United States) in 1997.
Jenex continues to further develop, and explore other
applications, for its platform technology. If you would like to stay informed
on the development of TherOZap™ please visit www.therozap.com.
About
Jenex:
Jenex is a progressive medical device technology company focused
on providing consumers with quality medical devices that address their
dermatological needs. Clear and healthy skin for all is at the core of Jenex's
philosophy as is the belief that such outcomes should not be a privilege for
only those who can afford costly procedures and treatments. The Company's
breakthrough proprietary technology delivers effective, non-invasive and pain
free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more
information visit: www.thejenexcorporation.com or www.therozap.com.
About
Techna Institute:
Techna is an institute of the University Health Network, in collaboration
with the University of Toronto, focused on the accelerated development and
exploitation of technology for improved health. Techna is designed to shorten
the time interval from technology discovery and development to application for
the benefit of patients and the health care system. It also stimulates and
facilitates the innovation cycle through a continuum of clinically driven
innovation, technology & process development, and translational research.
For more information visit: technainstitute.com.
About
University Health Network:
University Health Network (UHN) is a major landmark in Canada's
healthcare system and a teaching partner of the University of Toronto. UHN
consists of Toronto General and Toronto Western Hospitals, the Princess
Margaret Cancer Centre, Toronto Rehabilitation Institute and the Michener
Institute for Education at UHN. The scope of research and complexity of cases
at University Health Network has made it a national and international source
for discovery, education and patient care. It has the largest hospital-based
research program in Canada, with major research in cardiology, transplantation,
neurosciences, oncology, surgical innovation, infectious diseases, genomic
medicine and rehabilitation medicine. For more information visit: www.uhn.ca.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute
"forward-looking" statements. These statements relate to future
events or the Company's future performance and include tests involving the
Company's TherOZap™ technology and CBD oil from hemp as described in the news
release. All such statements involve substantial known and unknown risks,
uncertainties and other factors which may cause the actual results to vary from
those expressed or implied by such forward-looking statements. In addition to
other risks, the Company's tests involving TherOZap™ and CBD oil from hemp may
prove to be unsuccessful against the Zika or West Nile viruses and the Company
may be unable to complete the consumer product TherOZap™ technology. Further,
the Company may not complete the tests on the schedule it expects as described
in this news release or attract capital for marketing to ramp up sales or
establish recurring revenue in the future to generate cash flow for the
Company. Forward-looking statements involve significant risks and
uncertainties, they should not be read as guarantees of future performance or
results, and they will not necessarily be accurate indications of whether or
not such results will be achieved. Actual results could differ materially from
those anticipated due to a number of factors and risks. Although the
forward-looking statements contained in this news release are based upon what management
of the Company believes are reasonable assumptions on the date of this news
release, the Company cannot assure investors that actual results will be
consistent with these forward-looking statements. The forward-looking
statements contained in this press release are made as of the date hereof and
the Company disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information, future
events or otherwise, except as required under applicable securities
regulations.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this press release.
For
further information please contact:
The Jenex Corporation
Rob Fia
CEO & Chairman
rfia@thejenexcorporation.com
Rob Fia
CEO & Chairman
rfia@thejenexcorporation.com
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
I started chewing Blessed CBD gummies UK when my dad got sick. I was very worried, and I could not come to terms with this fact. A friend advised him to drink a course of CBD oil. And after a few days I began to notice changes. He felt much better, began to sleep better, and a good mood appeared in the morning!
ReplyDelete